Evading the immune response upon in vivo gene therapy with viral vectors

Brandon Wilder, R. W. Herzog

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Gene therapy has the potential to provide minimally invasive and long-term treatment for many inherited disorders that otherwise have poor prognoses and limited treatment options. The sustained therapeutic correction of genetic disease by viral gene transfer has been accomplished in patients with severe immune deficiencies, or by the transduction of an immune privileged site for the treatment of ocular disease. For other diseases and target tissues, immune responses to vectors or transgene products often present major obstacles for therapy. Innate and adaptive immunity, sometimes including pre-existing or memory responses, may contribute by varying degrees to immune-mediated rejection and immunotoxicity. This review provides an overview of the immune responses to in vivo gene transfer with the most commonly used viral gene therapy vectors, and discusses strategies and protocols employed in evading the immune system in order to provide optimal gene therapy.

Original languageEnglish (US)
Pages (from-to)493-503
Number of pages11
JournalCurrent Opinion in Molecular Therapeutics
Volume11
Issue number5
StatePublished - Oct 1 2009
Externally publishedYes

Fingerprint

Genetic Therapy
Viral Genes
Therapeutics
Inborn Genetic Diseases
Eye Diseases
Adaptive Immunity
Transgenes
Innate Immunity
Immune System
Genes
Transfer (Psychology)

Keywords

  • Adeno-associated virus
  • Adenovirus
  • Gene therapy
  • Immune tolerance
  • Immunity
  • Lentivirus

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this

Evading the immune response upon in vivo gene therapy with viral vectors. / Wilder, Brandon; Herzog, R. W.

In: Current Opinion in Molecular Therapeutics, Vol. 11, No. 5, 01.10.2009, p. 493-503.

Research output: Contribution to journalReview article

@article{462bb65373514255ab186a7c78aee627,
title = "Evading the immune response upon in vivo gene therapy with viral vectors",
abstract = "Gene therapy has the potential to provide minimally invasive and long-term treatment for many inherited disorders that otherwise have poor prognoses and limited treatment options. The sustained therapeutic correction of genetic disease by viral gene transfer has been accomplished in patients with severe immune deficiencies, or by the transduction of an immune privileged site for the treatment of ocular disease. For other diseases and target tissues, immune responses to vectors or transgene products often present major obstacles for therapy. Innate and adaptive immunity, sometimes including pre-existing or memory responses, may contribute by varying degrees to immune-mediated rejection and immunotoxicity. This review provides an overview of the immune responses to in vivo gene transfer with the most commonly used viral gene therapy vectors, and discusses strategies and protocols employed in evading the immune system in order to provide optimal gene therapy.",
keywords = "Adeno-associated virus, Adenovirus, Gene therapy, Immune tolerance, Immunity, Lentivirus",
author = "Brandon Wilder and Herzog, {R. W.}",
year = "2009",
month = "10",
day = "1",
language = "English (US)",
volume = "11",
pages = "493--503",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Evading the immune response upon in vivo gene therapy with viral vectors

AU - Wilder, Brandon

AU - Herzog, R. W.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Gene therapy has the potential to provide minimally invasive and long-term treatment for many inherited disorders that otherwise have poor prognoses and limited treatment options. The sustained therapeutic correction of genetic disease by viral gene transfer has been accomplished in patients with severe immune deficiencies, or by the transduction of an immune privileged site for the treatment of ocular disease. For other diseases and target tissues, immune responses to vectors or transgene products often present major obstacles for therapy. Innate and adaptive immunity, sometimes including pre-existing or memory responses, may contribute by varying degrees to immune-mediated rejection and immunotoxicity. This review provides an overview of the immune responses to in vivo gene transfer with the most commonly used viral gene therapy vectors, and discusses strategies and protocols employed in evading the immune system in order to provide optimal gene therapy.

AB - Gene therapy has the potential to provide minimally invasive and long-term treatment for many inherited disorders that otherwise have poor prognoses and limited treatment options. The sustained therapeutic correction of genetic disease by viral gene transfer has been accomplished in patients with severe immune deficiencies, or by the transduction of an immune privileged site for the treatment of ocular disease. For other diseases and target tissues, immune responses to vectors or transgene products often present major obstacles for therapy. Innate and adaptive immunity, sometimes including pre-existing or memory responses, may contribute by varying degrees to immune-mediated rejection and immunotoxicity. This review provides an overview of the immune responses to in vivo gene transfer with the most commonly used viral gene therapy vectors, and discusses strategies and protocols employed in evading the immune system in order to provide optimal gene therapy.

KW - Adeno-associated virus

KW - Adenovirus

KW - Gene therapy

KW - Immune tolerance

KW - Immunity

KW - Lentivirus

UR - http://www.scopus.com/inward/record.url?scp=70349918248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349918248&partnerID=8YFLogxK

M3 - Review article

C2 - 19806497

AN - SCOPUS:70349918248

VL - 11

SP - 493

EP - 503

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 5

ER -